Cancer Biomarkers Market Revenue 2025 to 2034
Cancer Biomarkers Market Revenue 2025 to 2034
Cancer Biomarkers Market (By Type: Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Others; By Biomolecule: Genetic, Epigenetic, Metabolic, Proteomic, Others; By Application: Drug Discovery & Development, Diagnostics, Personalized Medicine, Others; By Profiling Technology: Omic Technologies, Imaging Technologies, Immunoassays, Cytogenetics-based Tests; By End User: Hospitals, Academic & Cancer Research Institutes, Ambulatory Surgical Centres, Diagnostic Laboratories; By Geography: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) – Global Industry Analysis, Size, Trends, Leading Companies, Regional Outlook, and Forecast 2025 to 2034
Customisation Request
Revenue, 2025
USD 15.58 Bn
Forecast Year, 2034
USD 43.05 Bn
CAGR, 2025 - 2034
11.99%
Report Coverage
Worldwide
Published By
Saurabh Bidwai
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
The global cancer biomarkers market is experiencing strong growth, driven by rising cancer prevalence, advances in precision medicine, and increased adoption of early diagnostic tools. The market is expected to expand significantly through 2034, supported by ongoing R&D and personalized therapy demand.
Cancer Biomarkers Market Size Analysis
Cancer Biomarkers Market Size By Type 2025 to 2034 (USD Billion)
| Type | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Breast Cancer | 4.05 | 4.57 | 5.16 | 5.82 | 6.57 | 7.41 | 8.36 | 9.43 | 10.64 | 12.00 |
| Prostate Cancer | 2.18 | 2.46 | 2.77 | 3.13 | 3.53 | 3.98 | 4.49 | 5.06 | 5.71 | 6.43 |
| Colorectal Cancer | 2.34 | 2.63 | 2.97 | 3.35 | 3.77 | 4.25 | 4.79 | 5.40 | 6.09 | 6.86 |
| Cervical Cancer | 1.25 | 1.38 | 1.52 | 1.68 | 1.86 | 2.06 | 2.27 | 2.51 | 2.78 | 3.07 |
| Liver Cancer | 1.40 | 1.58 | 1.78 | 2.00 | 2.25 | 2.54 | 2.86 | 3.22 | 3.62 | 4.08 |
| Lung Cancer | 2.80 | 3.17 | 3.58 | 4.04 | 4.56 | 5.15 | 5.81 | 6.56 | 7.40 | 8.35 |
| Others | 1.56 | 1.66 | 1.76 | 1.86 | 1.96 | 2.06 | 2.15 | 2.24 | 2.31 | 2.37 |
Cancer Biomarkers Market Size By Biomolecule 2025 to 2034 (USD Billion)
| Biomolecule | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Genetic Biomarkers | 5.92 | 6.67 | 7.50 | 8.45 | 9.51 | 10.70 | 12.05 | 13.56 | 15.26 | 17.18 |
| Epigenetic Biomarkers | 3.12 | 3.51 | 3.95 | 4.44 | 5.00 | 5.63 | 6.33 | 7.13 | 8.02 | 9.02 |
| Metabolic Biomarkers | 2.18 | 2.45 | 2.76 | 3.10 | 3.48 | 3.91 | 4.40 | 4.94 | 5.55 | 6.24 |
| Proteomic Biomarkers | 2.80 | 3.16 | 3.56 | 4.00 | 4.51 | 5.08 | 5.72 | 6.44 | 7.25 | 8.16 |
| Others | 1.56 | 1.67 | 1.78 | 1.89 | 2.01 | 2.13 | 2.24 | 2.36 | 2.47 | 2.57 |
Cancer Biomarkers Market Size By Application 2025 to 2034 (USD Billion)
| Application | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Drug Discovery and Development | 4.99 | 5.61 | 6.31 | 7.10 | 7.99 | 8.99 | 10.11 | 11.38 | 12.80 | 14.40 |
| Diagnostics | 5.61 | 6.29 | 7.05 | 7.91 | 8.87 | 9.95 | 11.16 | 12.51 | 14.03 | 15.74 |
| Personalized Medicine | 3.43 | 3.86 | 4.34 | 4.88 | 5.49 | 6.18 | 6.95 | 7.81 | 8.79 | 9.89 |
| Others | 1.56 | 1.69 | 1.84 | 1.99 | 2.16 | 2.33 | 2.52 | 2.72 | 2.93 | 3.15 |
Cancer Biomarkers Market Size By Profiling Technology 2025 to 2034 (USD Billion)
| Profiling Technology | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Omic Technologies | 5.30 | 5.97 | 6.72 | 7.57 | 8.53 | 9.61 | 10.82 | 12.18 | 13.72 | 15.45 |
| Imaging Technologies | 3.27 | 3.67 | 4.12 | 4.63 | 5.20 | 5.83 | 6.55 | 7.35 | 8.25 | 9.26 |
| Immunoassays | 4.36 | 4.88 | 5.45 | 6.09 | 6.81 | 7.62 | 8.51 | 9.52 | 10.64 | 11.89 |
| Cytogenetics-based Tests | 2.65 | 2.93 | 3.24 | 3.59 | 3.97 | 4.39 | 4.86 | 5.37 | 5.94 | 6.56 |
Cancer Biomarkers Market Size By End User 2025 to 2034 (USD Billion)
| End User | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | 5.45 | 6.12 | 6.86 | 7.69 | 8.63 | 9.67 | 10.85 | 12.17 | 13.65 | 15.30 |
| Academic and Cancer Research Institutes | 3.74 | 4.20 | 4.73 | 5.32 | 5.98 | 6.72 | 7.56 | 8.50 | 9.56 | 10.75 |
| Ambulatory Surgical Centres | 2.49 | 2.80 | 3.15 | 3.53 | 3.97 | 4.46 | 5.01 | 5.63 | 6.32 | 7.10 |
| Diagnostic Laboratories | 3.90 | 4.33 | 4.81 | 5.34 | 5.93 | 6.59 | 7.32 | 8.12 | 9.02 | 10.02 |
Cancer Biomarkers Market Size By Geography 2025 to 2034 (USD Billion)
| Geography | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| North America | 5.92 | 6.60 | 7.35 | 8.18 | 9.12 | 10.15 | 11.31 | 12.60 | 14.03 | 15.63 |
| Europe | 4.21 | 4.69 | 5.24 | 5.84 | 6.52 | 7.27 | 8.11 | 9.05 | 10.10 | 11.27 |
| Asia-Pacific | 3.58 | 4.08 | 4.65 | 5.30 | 6.03 | 6.86 | 7.81 | 8.88 | 10.10 | 11.48 |
| Latin America | 1.09 | 1.21 | 1.35 | 1.50 | 1.67 | 1.85 | 2.06 | 2.29 | 2.54 | 2.83 |
| Middle East & Africa (MEA) | 0.78 | 0.86 | 0.96 | 1.06 | 1.18 | 1.30 | 1.44 | 1.60 | 1.77 | 1.96 |
Cancer Biomarkers Market Size to Reach USD 43.05 Billion by 2034
The global cancer biomarkers market size was estimated at USD 15.58 billion in 2025 and is projected to be worth around USD 43.05 billion by 2034 with a CAGR of 11.99%
Proceed To Buy
Proceed To CheckoutMake Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Quick Contact
- NA : +1 804 441 9344
- APAC : +91 9356 9282 04
- EU : +44 7782 560 738
- sales@precedenceresearch.com
